0
XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma
Includes royalty interest in NIR178 September 30 2019 XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L. One of the assets, NIR178, is being developed by...